MSMatheo Augusto Morandi Stumpf

Matheo Augusto Morandi Stumpf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matheo Augusto Morandi Stumpf has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring the SPARAGMOS Study Protocol: review of a high-dose cabergoline interventional trial in microprolactinomas

    by Matheo A. M. Stumpf, Andrea Glezer

    Prolactinoma is the most common functional pituitary tumor, accounting for up to 40% of pituitary adenomas. Dopamine agonists (DA) are usually the treatment of choice, with cabergoline (CAB) genera...

  • Open Access

    Refractory Headache in Macroprolactinoma Resolved After Neurosurgery: A Challenging Clinical Case and Literature Review

    by Matheo A. M. Stumpf, Leonardo Andrade Gontijo Tavares, Nara L. Queiroz, Marcio Nattan Portes Souza, Ida Fortini, Isabella Cajuela Marin, Matheus Louzada Yamaki, Valter Angelo Sperling Cescato, Andrea Glezer

    Pituitary tumors are present in approximately 15% of the population and are often discovered incidentally during imaging for headache evaluation. Headaches are prevalent in patients with pituitary adenomas, occurring in 37-70% of cases. However, determining whether the tumor itself causes the pain is frequently challenging. A 27-year-old woman presented with progressive daily holocranial headaches, photophobia, phonophobia, nausea, and secondary amenorrhea. Laboratory tests and pituitary imaging confirmed a macroprolactinoma. Initial treatment with cabergoline and bromocriptine was unsuccessful due to intolerable side effects. Transsphenoidal surgery produced marked clinical improvement and a partial reduction in serum prolactin. However, tumor regrowth occurred with recurrence of daily headaches, and a second surgery was delayed due to the COVID-19 pandemic. Multiple medical treatments, which included topiramate, divalproex sodium, amitriptyline, propranolol, and riboflavin with magnesium resulted in no improvement. After the second neurosurgery, she presented normoprolactinemia with no residual tumor and once again a complete resolution of the headache episodes. Risk factors for headache related to adenoma include high prolactin or IGF-1 levels, cavernous sinus invasion (but not adenoma size), and a history of primary headache disorder. International diagnosis criteria emphasize headache resolution following endocrine normalization or tumor removal. This case highlights the intricate relationship between prolactinomas and headaches, underscoring the need for individualized treatment strategies.

  • Approach to the Patient With Dopamine-Resistant Microprolactinoma

    by Andrea Glezer, Matheo Augusto Morandi Stumpf, Nara Lima Queiroz

    Prolactinoma is a significant cause of hyperprolactinemia and the most common type of pituitary tumor. Women of fertile age are most commonly affected, and the clinical picture is characterized by galactorrhea, oligo-amenorrhea, and infertility. In microprolactinomas, which represent more than 60% of cases in women before menopause, there is usually no concern about the mass effect. Therefore, management can be expectant if there are no symptoms or in a patient in the postmenopausal period; oral contraceptive in the presence of hypogonadism and no desire for pregnancy; dopamine agonist (DA) in the presence of bothersome galactorrhea, hypogonadism, and the desire for fertility; and neurosurgery in selected noninvasive cases. Resistance to DA occurs in less than 10% of cases. Although the reduction in dopamine receptor subtype 2 expression is considered the primary cause of DA resistance, the underlying mechanisms are not yet completely elucidated. The main concern in resistant cases is the risk of symptomatic tumor growth during assisted reproduction techniques and pregnancy. Other conditions in which hyperprolactinemia could be implicated, such as metabolic parameters, osteoporosis, and breast cancer risk are also discussed. Understanding the mechanisms of DA resistance can lead to the opening of new treatment strategies.


  • Open Access

    A new and useful tool for differentiating prolactinomas from non-functioning pituitary adenomas: a pilot study of the cabergoline disconnection test

    by Stefano Alvarenga Galliano, Matheo Augusto Morandi Stumpf, Nara L. Queiroz, Eduardo Henrique Rodrigues Ferreira, Flora Ladeira Craveiro, Christiane Gruetzmacher, Gilberto Ochman da Silva, Valter Angelo Sperling Cescato, Eduardo Arnaldo Silva Vellutini, Malebranche Berardo Carneiro Cunha-Neto, et al.

    Highlights ■ Hyperprolactinemia can be present in non-functioning pituitary adenomas because of the stalk effect. ■ Absolute prolactin levels may not always be reliable in discriminating non-functioning pituitary adenomas from prolactinomas. ■ Prolactin normalization after 48 h of 0.25mg cabergoline intake could be a strong predictor of non-functioning pituitary adenomas (100% sensitivity and specificity). ABSTRACT Objective: Clinical, imaging, and laboratory differentiation between non-functioning pituitary adenomas (NFPAs) and prolactinomas can be challenging in clinical practice because of their similar presentation and


  • Open Access

    Combination of sibutramine and topiramate for the treatment of obesity: the SIBAMATE retrospective cohort study

    by Cintia Cercato, Matheo A. M. Stumpf, Gabriel Neimann da Cunha Freire, Eduardo Zanatta Kawahara, Ariana E. Fernandes, Maria E. de Melo, Marcio C. Mancini

    Background: Long-term treatment of obesity with lifestyle changes alone is unsustainable for most individuals. Antiobesity medications are recommended for individuals with a body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² with one or more comorbidities. In Brazil, the prescription of combined sibutramine plus topiramate for obesity management is common in daily clinical practice. However, data on its effectiveness and safety are lacking. Thus, the objective of this study was to evaluate this combination for treating obesity in a real-world scenario. Methods: This retrospective cohort study included individuals with obesity ≥ 18 years prescribed sibutramine and topiramate for at least 3 months between 2012 and 2022 at a large tertiary healthcare center. Baseline and follow-up data were collected from medical records. Results: Among 861 medical records screened, 246 (28.6%) were included. Most participants were female (86.2%) with a mean age of 42.8 ± 12.7 years, 52% had hypertension, 31.3% type 2 diabetes and 30% dyslipidemia. The average baseline BMI and weight were 39.7 kg/m² and 104.2 kg, respectively. The mean daily doses of sibutramine and topiramate were 11 ± 2.1 mg and 119.7 ± 54.7 mg, respectively. There was a significant change in body weight precociously at 3 months on the combination (96.8 ± 20.7 kg, p < 0.001), with 61.8% of patients achieving at least ≥ 5% of weight loss, 29.4% ≥10% and 10.9% ≥15%. At 36 months, 64% maintained at least ≥ 5% of weight loss, 40.6% ≥10% and 26.5% ≥15%. Common adverse effects included paresthesia, memory impairment, bradyphrenia and elevated blood pressure. The discontinuation rate was 24.4%. No major safety concern was observed in a mean follow-up of 25.3 months. Conclusion: In a real-world setting, sibutramine and topiramate combination therapy was associated with clinically meaningful weight loss alongside a good tolerability profile.


  • Ectopic GHRH production: revisiting a rare cause of acromegaly

    by Matheo A. M. Stumpf, Nathalie Oliveira Santana, Marcio Carlos Machado, Felipe H. Duarte, Andrea Glezer, Gérald Raverot, Véronique Raverot, Raquel S. Jallad

    Growth Hormone-Releasing Hormone (GHRH) is a hypothalamic hormone that stimulates GH secretion by the anterior pituitary gland. Ectopic production of GHRH by neuroendocrine tumors (NETs) is a rare cause of acromegaly, with some clinical and biochemical features indistinguishable from pituitary adenoma origin. Some clues for this diagnosis include pituitary MRI harboring hyperplasia, increased serum GHRH and extra-pituitary tumor detected in whole body scans. The preferable treatment, when possible, should be surgical resection of the NET. In cases with residual tumor, somatostatin analogs could be used as an alternative for adjuvant therapy for both tumoral and biochemical control of IGF-1. Life-long follow-up is needed as some patients may develop persistent pituitary hyperplasia or GH-adenomas due to prolonged GHRH exposure, with elevated IGF-1 levels even without NET recurrence. In such scenarios, medical therapy should be provided for hyperplasia cases and transsphenoidal surgery to patients with pituitary adenoma. If available, genetic test for MEN1 mutations should always be performed.


  • Sheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery

    by Matheo Augusto Morandi Stumpf, Cintia Cercato, Maria E. de Melo, Marcio C. Mancini

    The global prevalence of obesity among elderly patients continues to rise. Despite the availability of new antiobesity medications, bariatric surgery remains an effective treatment option for carefully selected candidates. However, it is not risk-free, especially in a vulnerable population, predisposing to falls, fractures and sarcopenia. Following bariatric surgery, there is rapid loss of muscle mass, particularly within the first 3 months. Muscle quality, on the other hand, characterized by functionality and indirectly assessed through strength tests, appears to be preserved. This is attributed to reductions in ectopic intramuscular fat deposits. Strategies to mitigate muscle loss and functional impairment include combined exercises (resistive and aerobic training), adequate protein and vitamin D intake, beta-hydroxy-beta-methylbutyrate (HMB) supplementation, and testosterone replacement therapy for men with confirmed hypogonadism. It is important to emphasize that, to date, no specific trial has evaluated the current sarcopenia criteria in elderly patients undergoing bariatric surgery. Therefore, future studies are needed to assess this particularly vulnerable population, not only to monitor changes in muscular health, but also to develop strategies for preventing therapeutic inertia.


  • Open Access

    Challenges in the care and treatment of patients with extreme obesity

    by Matheo A. M. Stumpf, Marcio C. Mancini

    Obesity is a prevalent chronic disease. The management of extreme obesity – i.e., body mass index (BMI) ≥ 50 kg/m2 or obesity class IV and V – is still far from ideal. Individuals with extreme obesity have a high risk of surgical complications, mortality, comorbidities, and reduced weight loss following bariatric surgery. Although lifestyle changes and anti-obesity medications are recommended for all patients with extreme obesity as adjuvants to weight loss, these measures are less effective than bariatric surgery. [...] ABSTRACT Obesity is a prevalent chronic disease. The management of extreme obesity – i.e., body mass index (BMI) ≥ 50 kg/m2 or obesity class IV and V – is still far from ideal. Individuals with extreme obesity have a high risk of surgical complications, mortality, comorbidities, and reduced weight loss following bariatric surgery. Although lifestyle changes and anti-obesity medications are recommended for all patients with extreme obesity as adjuvants to weight loss, these measures are less effective than bariatric surgery.


  • Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism

    by Matheo A. M. Stumpf, Stefano A. Galliano, Cristina B. F. Bueno, Andrea Glezer

    Background Men with macroprolactinoma can present persistent hypogonadism despite normoprolactinemia achieved with clinical and/or neurosurgical treatment. Usually, testosterone replacement therapy is indicated. Nevertheless, although off-label, clomiphene citrate (CC), a selective estrogen receptor modulator, has also been used, mainly when fertility is an issue. The aim of this study is to evaluate the effectiveness of CC in recovering the gonadal axis in men with macroprolactinoma, with or without hyperprolactinemia, and evaluate its safety as a long-term therapy. Methods This is a retrospective study including 10 men with macroprolactinoma on cabergoline treatment and persistent hypogonadism. All patients received initially 50 mg/d of CC. Results The median age at diagnosis of prolactinomas was 34 (range, 26–60) years old. All patients were treated with cabergoline at a median maximum dose of 2 (1–7) mg/week, with a median time of treatment of 8.5 (2–15) years. Prolactin was still above the normal range when CC was introduced only in two patients. The mean duration of CC therapy was 3.2 (±2.8) years. Prolactin levels maintained stable (p = 0.252) and testosterone increased (p = 0.027) significantly on CC therapy. Tumor size remained stable. Eight patients (80%) maintained testosterone above 300 ng/dL and were classified as responders. Three responders succeeded in using a lower dose of CC and one of them completed withdrawal CC and maintained eugonadism. There were no side effects or safety concerns reported. Conclusion CC should be seen as a safe treatment option for men with macroprolactinoma and persistent hypogonadism.